Thrombolytic Science International
Phase 2TSI is to transform the treatment of thrombotic diseases like ischemic stroke, by taking its drug to the patient, instead of taking the patient to the drug, dramatically improving patient access to a life-saving solution. Only an intravenous Rx can restore blood flow close to the time of onset.
Founded
2003
Focus
Small Molecules
About
TSI is to transform the treatment of thrombotic diseases like ischemic stroke, by taking its drug to the patient, instead of taking the patient to the drug, dramatically improving patient access to a life-saving solution. Only an intravenous Rx can restore blood flow close to the time of onset.
Funding History
2Total raised: $5.5M
Series A$5MUndisclosedJun 15, 2017
Grant$500KNational Institutes of HealthJun 15, 2015
Company Info
TypePrivate
Founded2003
LocationCambridge, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile